Enterprise Value

81.31M

Cash

22.86M

Avg Qtr Burn

-8.039M

Short % of Float

0.70%

Insider Ownership

12.04%

Institutional Own.

29.18%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

BLA

Submission

Vilobelimab (IFX-1) Details
Skin disease/disorder, Autoimmune disease, Pyoderma gangraenosum

Phase 3

Data readout

INF904 (C5aR Inhibitor) Details
Chronic Autoimmune and Inflammatory Diseases

Phase 2

Initiation

Vilobelimab (IFX-1) Details
Cancer, Cutaneous squamous cell carcinoma

Failed

Discontinued

IFX-1 (vilobelimab) Details
Skin disease/disorder, Hidradenitis suppurativa

Failed

Discontinued

IFX-1 (vilobelimab) Details
Autoimmune disease, Antineutrophil cytoplasmic antibody-associated vasculitis

Failed

Discontinued